Search Results
Oct 01, 2025, 11:04 ET BioMarin apresenta novos dados que reforçam sua liderança em saúde óssea na reunião anual da Sociedade Americana de Pesquisa Óssea e Mineral
ScienceDirect. https://www. sciencedirect.com/science/article/pii/S875632822100034X?via%3Dihub Published February 3, 2021. 3 Ornitz DM, Itoh N. The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015 May-Jun;4(3):215-66. doi: 10.1002/wdev.176. Epub 2015 Mar
More news about: BioMarin
Sep 30, 2025, 08:00 ET Seed Redefines Daily Supplementation With the Launch of Co-Biotics -- A New Category of Targeted Innovations for the Body and Microbiome
biological process, targeting both human and microbial pathways to maximize the benefits of daily supplementation. Seed's first three Co-Biotic formulations—DM-02™ Daily Multivitamin, AM-02™ Energy + Focus, and PM-02™ Sleep + Restore—are engineered to support the interconnected systems underpinning nutrient
More news about: Seed Health
Sep 30, 2025, 07:00 ET ANDERSON .PAAK EARNS HIS PHD (PIZZA HUT DEGREE) IN NEW COLLABORATION WITH PIZZA HUT CELEBRATING THE LAUNCH OF CRAFTED FLATZZ™
join the fun with a chance to earn their very own PHD (Pizza Hut Degree) and claim one of 777 free Crafted Flatzz™ pizzas*. Starting at 11am CT today, DM the word "PHD" to @pizzahut on Instagram and the first 777 fans to reply will score a $12 e-gift card — enough to cover a free Crafted Flatzz™ — along
More news about: Pizza Hut
Sep 29, 2025, 09:00 ET AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)
a first-in-class antibody drug conjugate (ADC) composed of a folate receptor alpha binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin inhibitor designed to kill the targeted cancer cells. Mirvetuximab soravtansine (approved under the brand name
More news about: AbbVie
Sep 23, 2025, 17:31 ET SGLT2 Inhibitors Market to Expand by 2034 as Companies Leverage Emerging Opportunities in Indications Such as Heart Failure, MASH, Obesity, PCOS, and Others | DelveInsight
cystic fibrosis, T1DM, diabetes with advanced chronic kidney disease, and heart failure. Jeil Pharmaceuticals' JP-2266 is another small-molecule dual SGLT1/2 inhibitor in Phase II development. It is being studied for T2DM to improve glycemic control, as well as for T1DM in patients who remain
More news about: DelveInsight Business Research, LLP
Sep 23, 2025, 04:57 ET Kelun-Biotech to Present Results from Multiple Clinical Studies at the 2025 ESMO Congress
October 18, 10:45 AM to 10:55 AM local time Title: Trastuzumab botidotin vs trastuzumab emtansine (T-DM1) in HER2-positive unresectable or metastatic breast cancer: results from a randomized phase 3 studyPresentation Type: Proffered Paper presentation
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Sep 22, 2025, 11:15 ET Cardiology Experts Warn of Growing Heart Failure Epidemic and Soaring Costs in New HF Stats 2025 Report
(Stage A), and 24-34% of the U.S. population has pre-HF (Stage B). The risk of developing HF is increased in individuals with obesity, diabetes mellitus (DM), hypertension, and chronic kidney disease. When comparing 1999-2002 to 2015-2020 data, the proportion of individuals having 3 cardiovascular-kidney-metabolic
More news about: Heart Failure Society of America
Sep 19, 2025, 15:01 ET FTX Recovery Trust to Distribute Approximately $1.6 Billion to Creditors in Third Distribution on September 30, 2025
https://cases.ra.kroll.com/FTX/. FTX Digital Markets Ltd. ("FTX DM") will be separately communicating distribution information for customers who have elected to have their claims administered by FTX DM. Advisors The FTX Recovery Trust is represented by Sullivan &
More news about: FTX
Sep 17, 2025, 07:00 ET BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years
Armstrong A, Gudjonsson J, et al. Psoriasis. Lancet. 2021;397(10281):1301–15.11. Griffiths CEM, van der Walt JM, Ashcroft DM, et al. The global state of psoriasis disease epidemiology: a workshop report. Br J Dermatol. 2017;177(1):e4-e7. 12. Ogdie
More news about: UCB
Sep 17, 2025, 03:00 ET ARTHEx Biotech Upsizes Series B Financing Round to $87M to Advance Lead Program ATX-01 in Myotonic Dystrophy Type 1 and Expand Pipeline of Targeted RNA Medicines
for DM1 aiming at targeting miR-23b has demonstrated compelling in vitro and in vivo results. The dual mechanism of action of ATX-01 offers real potential to be the best-in-class treatment for DM1. In addition, the Company's delivery platform enables uptake into multiple tissues affected by DM1, allowing
More news about: ARTHEx Biotech
Sep 15, 2025, 16:01 ET Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology
More news about: Avidity Biosciences, Inc.
Sep 15, 2025, 09:00 ET PayPal Ushers in a New Era of Peer-to-Peer Payments, Reimagining How Money Moves to Anyone, Anywhere
person – Each link is private, one-time use, and created for a specific transaction.Drop it anywhere – Send your link in a text, DM, email, or chat. Add a note, emoji, or payment note.Manage payment activity: Unclaimed links expire after 10 days. Users can send a reminder
More news about: PayPal Holdings, Inc.
Sep 15, 2025, 08:00 ET AMO Pharma Reports Long-Term Safety Data from REACHCDM-X Study of AMO-02 in Treatment of Congenital Myotonic Dystrophy Type 1
company's ongoing REACHCDM-X open-label extension (OLE) study of AMO-02 for the treatment of congenital and childhood-onset myotonic dystrophy type 1 (DM1).
More news about: AMO Pharma Limited
Sep 15, 2025, 08:00 ET AMO Pharma Reports Long-Term Safety Data from REACHCDM-X Study of AMO-02 in Treatment of Congenital Myotonic Dystrophy Type 1
company's ongoing REACHCDM-X open-label extension (OLE) study of AMO-02 for the treatment of congenital and childhood-onset myotonic dystrophy type 1 (DM1).
More news about: AMO Pharma Limited
Sep 11, 2025, 19:56 ET Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock
targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology
More news about: Avidity Biosciences, Inc.